CRISPR Therapeutics AG (NASDAQ: CRSP) flaunted slowness of -4.88% at $50.43, as the Stock market unbolted on Thursday, before settling in for the price of $53.02 at the close. Taking a more long-term approach, CRSP posted a 52-week range of $36.52-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 31550.17%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -10.48%. This publicly-traded company’s shares outstanding now amounts to $85.74 million, simultaneously with a float of $82.09 million. The organization now has a market capitalization sitting at $4.33 billion. At the time of writing, stock’s 50-day Moving Average stood at $42.81, while the 200-day Moving Average is $49.49.
CRISPR Therapeutics AG (CRSP) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the CRISPR Therapeutics AG industry. CRISPR Therapeutics AG’s current insider ownership accounts for 4.30%, in contrast to 69.43% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s Chief Executive Officer sold 11,640 shares at the rate of 55.05, making the entire transaction reach 640,782 in total value, affecting insider ownership by 196,901. Preceding that transaction, on Feb 19 ’25, Company’s Chief Executive Officer sold 6,928 for 52.80, making the whole transaction’s value amount to 365,798. This particular insider is now the holder of 189,973 in total.
CRISPR Therapeutics AG (CRSP) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
CRISPR Therapeutics AG’s EPS decrease for this current 12-month fiscal period is -10.48% and is forecasted to reach -3.99 in the upcoming year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Let’s observe the current performance indicators for CRISPR Therapeutics AG (CRSP). It’s Quick Ratio in the last reported quarter now stands at 22.07. The Stock has managed to achieve an average true range (ATR) of 2.98. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 115.94.
In the same vein, CRSP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.36, a figure that is expected to reach -1.24 in the next quarter, and analysts are predicting that it will be -3.99 at the market close of one year from today.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Now, what If we examine the latest scores posted by [CRISPR Therapeutics AG, CRSP]. During the last 5-days, its volume was better the volume of 2.43 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 78.23% While, its Average True Range was 3.34.
Raw Stochastic average of CRISPR Therapeutics AG (CRSP) in the period of the previous 100 days is set at 61.69%, which indicates a major fall in contrast to 69.03% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 78.08% that was higher than 55.88% volatility it exhibited in the past 100-days period.
